Analyst on competition in the obesity market: There is room for both Novo Nordisk and Eli Lilly
”I believe that with the demand we see, there is plenty of room in the obesity treatment market,” says Sydbank’s Søren Løntoft Hansen.
by marketwire
Novo Nordisk has long struggled to keep up with demand for obesity treament Wegovy, and will probably be able to sell its weight loss drug as fast as it can be produced in the next few years. This is true even if there is competition from arch-rival Eli Lilly.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
